Investor Hub

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases.

Latest investor presentation
Latest clinical presentation
Latest quarterly earnings
Annual report
Global ticker
NASDAQNVAX
NASDAQNVAX
FormDescriptionDateFormat
10-K/AAmendment to a previously filed 10-KApr 29, 2021Open Amendment to a previously filed 10-K in HTML.Open Amendment to a previously filed 10-K in DOC file.Open Amendment to a previously filed 10-K in PDF file.Open Amendment to a previously filed 10-K in XLS file.Open Amendment to a previously filed 10-K in XBLR Viewer.Open Amendment to a previously filed 10-K in XBLR file.
10-KAnnual report which provides a comprehensive overview of the company for the past yearMar 1, 2021Open Annual report which provides a comprehensive overview of the company for the past year in HTML.Open Annual report which provides a comprehensive overview of the company for the past year in DOC file.Open Annual report which provides a comprehensive overview of the company for the past year in PDF file.Open Annual report which provides a comprehensive overview of the company for the past year in XLS file.Open Annual report which provides a comprehensive overview of the company for the past year in XBLR Viewer.Open Annual report which provides a comprehensive overview of the company for the past year in XBLR file.
Why invest with us

We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.

For much of my four-decade career, I’ve worked with biotech companies trying to solve significant health challenges, including HIV. Novavax is uniquely positioned to help end this pandemic with our protein-based vaccine. I believe in NVX-CoV2373 so much.

I came out of retirement to join the fight.

Lisa Dunkle
Vice President, Global Medical Lead for Coronavirus Vaccine

Get notifications for investor updates

Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings, and more.

Go to email subscription 

Investor inquiries

Shareholders seeking information can contact investor relations at (240) 268-2022 or email us at ir@novavax.com

Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.